Walleye Capital
VYGR icon

Walleye Capital’s Voyager Therapeutics VYGR Stock Holding History

Walleye Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,840
Closed -$219K – 5043
2025
Q4 		$219K Buy
+55,840
New +$247K ﹤0.01% 3497
2023
Q4 		– Sell
-13,262
Closed -$103K – 5577
2023
Q3 		$103K Sell
13,262
-136,766
-91% -$1.25M ﹤0.01% 3926
2023
Q2 		$1.72M Buy
+150,028
New +$1.55M 0.01% 1432
2022
Q4 		– Sell
-127,014
Closed -$752K – 3669
2022
Q3 		$752K Buy
127,014
+88,108
+226% +$564K 0.01% 1168
2022
Q2 		$230K Sell
38,906
-111,761
-74% -$755K 0.01% 1454
2022
Q1 		$1.15M Buy
+150,667
New +$672K 0.03% 574
2021
Q4 		– Sell
-16,069
Closed -$42 – 2341
2021
Q3 		$42 Buy
+16,069
New +$52.2K ﹤0.01% 1407

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Capital's VYGR Position: Q1 2026 in Review

Walleye Capital sold out of Voyager Therapeutics (VYGR) in Q1 2026, closing a stake of 55,840 shares — an estimated $219K sold.

Walleye Capital first reported a position in VYGR in Q3 2021 and held it in 7 quarters. The position peaked at $1.72M in Q2 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Walleye Capital reported no remaining Voyager Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 55,840 Voyager Therapeutics shares in Q1 2026, an estimated $219K.
  • Walleye Capital first reported a position in Voyager Therapeutics in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's Voyager Therapeutics position peaked at $1.72M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.